A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Janssen Biotech announced new five-year data from three pivotal Phase 3 studies evaluating Simponi (golimumab) 50mg administered subcutaneously once every four weeks in the treatment of moderately to ...
First Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis "Phase 3 data showed treatment with SIMPONI ARIA plus ...
rheumatoid arthritis and ankylosing spondylitis in adults psoriatic arthritis in adults and children ages 2 years and older polyarticular juvenile idiopathic arthritis in children ages 2 years and ...
Janssen Biotech announced new Phase 3 study findings which showed significantly more patients with moderately to severely active ulcerative colitis (UC) who responded to induction therapy with ...
Simponi works by blocking tumor necrosis factor (TNF), which plays an important role in causing abnormal inflammatory and immune responses. Previously approved to treat rheumatoid arthritis, psoriatic ...
Sometimes follow-on drugs are flubs that would have been better put in the trash can, but I don't think that'll be the case for Johnson & Johnson's (NYSE:JNJ) Simponi: it was approved on Friday for ...
The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis. Simponi works by blocking tumor necrosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results